News

The European Medicines Agency (EMA) has started evaluation of the data on a booster (third) dose for the Covid-19 vaccine, Comirnaty, developed by Pfizer and BioNTech. The move

This trial will evaluate the safety, tolerability and immunogenicity of Reliance’s vaccine against Covid-19 infection in healthy subjects. The trial will also analyse the maximum tolerated dose of

The US Food and Drug Administration (FDA) has granted fast track designation for Novartis’ agonist LNA043 to treat knee osteoarthritis. LNA043, which has been discovered within the Novartis

Swedish Orphan Biovitrum (Sobi) has agreed a $8bn (SEK69.4bn) takeover offer from Advent International and Singapore’s wealth fund GIC. Sobi’s board of directors had unanimously recommended that shareholders

Moderna has initiated its submission process for the evaluation of a booster dose of its Covid-19 vaccine at the 50µg dose level, to the US Food and Drug

Merck and Ridgeback Biotherapeutics have initiated a Phase III clinical trial to evaluate investigational oral antiviral therapeutic molnupiravir to prevent Covid-19 infection. For the global MOVe-AHEAD study, individuals

Teva Pharmaceuticals and MedinCell’s new drug application (NDA) for their drug, TV-46000/mdc-IRM to treat schizophrenia has been accepted by the US Food and Drug Administration (FDA). Intended for

Claimed to have high clinical potential to treat Covid-19, Silmitasertib acts on the protein kinase CK2 pathway. As a CK2-inhibitor, it is believed to hinder the active viral

The US Food and Drug Administration (FDA) has approved an expanded indication for UCB’s Briviact (brivaracetam) CV as monotherapy or adjunctive therapy for the treatment of partial-onset seizures